Porterfield, Lowenthal & Fettig
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying Carried Out by Porterfield, Lowenthal & Fettig
Names of Lobbyists
Client Amount Coalition of Private Investment Cos $780,000 Promontory Interfinancial Network $610,000 NASDAQ OMX Group $480,000 State Farm Insurance $460,000 TIAA-CREF $370,000 Massachusetts Mutual Life Insurance $350,000 Jefferies & Co $320,000 Manufactured Housing Institute $320,000 Vanguard Group $250,000 New York Metro Transportation Authority $240,000
Most Frequently Disclosed Lobbying Issues
- Fed Budget & Appropriations,
Most Frequently Disclosed Bills
Bill No. Title H.R.4173 Prevent Iran from Acquiring Nuclear Weapons and Stop War Through Diplomacy Act H.R.4173 Wall Street Transparency and Accountability Act of 2010 H.R.1309 Flood Insurance Reform Act of 2011 H.R.3606 Reopening American Capital Markets to Emerging Growth Companies Act of 2011 H.R.2086 Medical Debt Responsibility Act of 2011 H.R.1224 GSE Portfolio Risk Reduction Act of 2011 H.R.1070 Small Company Capital Formation Act of 2011 H.R.3849 Preserving Access to Manufactured Housing Act S.1933 Reopening American Capital Markets to Emerging Growth Companies Act of 2011 S.2149 Medical Debt Responsibility Act of 2012
Recent Lobbying Contracts
Date Client Summary March 2, 2015 National Auto Dealers Assn General issues pertaining to the financing and sale of automobiles. View registration Jan. 30, 2015 Charter Communications General issues related to telecommunications View registration Jan. 7, 2015 Nestle Waters North America General issues pertaining to the bottled water industry. View registration Dec. 15, 2014 Astellas Pharma USA General issues pertaining to pharmaceuticals, life sciences, and healthcare. View registration
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.